文献速递产科

缩宫素与口服米索前列醇用于未产、宫颈不成熟胎膜早破引产的随机试验

Oxytocin vs oral misoprostol for PROM induction in nulliparas with unfavorable cervix: a randomized trial.
PubMed 文献 · Am J Obstet Gynecol MFM · 2024-06-25

本研究为在城市三级医疗中心2019至2023年开展的随机临床试验,纳入108例≥36周、宫颈不成熟(≤2 cm且Bishop<8)的未产胎膜早破患者,比较缩宫素与口服米索前列醇至分娩时间。总体至分娩时间无统计学差异(缩宫素14.9小时 vs 口服米索前列醇18.1小时,P=.06);BMI≥30 kg/m2亚组缩宫素缩短5小时(16.6 vs 21.8小时,P=.04),宫颈扩张≥1 cm亚组缩短4.5小时(12.9 vs 17.3小时,P=.04)。患者满意度缩宫素组更高(29.0 vs 26.3,P=.03)。研究因招募可行性问题提前终止,结果需谨慎解读。

要点

  • 总体至分娩时间缩宫素14.9小时 vs 口服米索前列醇18.1小时,无统计学差异(P=.06)。
  • BMI≥30 kg/m2者缩宫素至分娩时间较口服米索前列醇缩短5小时(16.6 vs 21.8小时,P=.04)。
  • 宫颈扩张≥1 cm者缩宫素至分娩时间较口服米索前列醇缩短4.5小时(12.9 vs 17.3小时,P=.04)。

核心结论

  • 在胎膜早破且宫颈不成熟的未产妇中,缩宫素与口服米索前列醇的总体至分娩时间无差异。
  • 鉴于研究提前终止和把握度不足,该结果应谨慎解读。
  • 在肥胖患者和宫颈扩张至少1 cm者中观察到缩宫素至分娩时间更短。
  • 缩宫素组患者满意度更高,且未增加母儿发病率风险。

研究设计与样本

  • 随机临床试验,2019至2023年在城市三级医疗中心开展。
  • 纳入≥36周、起始宫颈检查不成熟(≤2 cm且Bishop<8)的未产妇。
  • 共108例随机分组:缩宫素组56例,口服米索前列醇组52例。
  • 主要结局为引产至分娩时间(小时),次要结局包括疑似羊膜腔内感染、剖宫产、母儿复合发病率及患者满意度(采用修订版分娩满意度量表评估)。
  • 预设需148例受试者以80%把握度检测至分娩时间2小时差异;数据安全监查委员会因招募预期样本量可行性问题提前终止研究。

主要发现

  • 引产时中位孕周39.5周,平均起始宫颈扩张1.1 cm。
  • 总体至分娩时间:缩宫素14.9小时 vs 口服米索前列醇18.1小时(P=.06),无统计学差异。
  • BMI≥30 kg/m2亚组:缩宫素16.6小时 vs 口服米索前列醇21.8小时(P=.04),缩宫素缩短5小时。
  • 宫颈扩张≥1 cm亚组:缩宫素12.9小时 vs 口服米索前列醇17.3小时(P=.04),缩宫素缩短4.5小时。
  • 两组间羊膜腔内感染、剖宫产、母体或新生儿发病率无差异;患者满意度缩宫素组高于米索前列醇组(29.0 vs 26.3,P=.03)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 研究因招募预期样本量可行性问题被数据安全监查委员会提前终止。
  • 研究把握度不足。
  • 结果应谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Induction of labor (IOL) is recommended following prelabor rupture of membranes (PROM). The optimal method for IOL and need for cervical ripening in those with PROM and an unfavorable cervical examination is unclear. OBJECTIVE: To determine if oxytocin or oral misoprostol results in a shorter time to delivery among nulliparous patients with an unfavorable cervical examination and PROM diagnosis and to evaluate patient satisfaction with both methods. STUDY DESIGN: This is a randomized clinical trial conducted at an urban tertiary care center from 2019 to 2023. Subjects were nulliparas ≥36 weeks with an unfavorable starting cervical exam (≤2 cm and Bishop <8). The primary outcome was time from IOL to delivery in hours compared between oxytocin vs oral misoprostol. Secondary outcomes included suspected intraamniotic infection, cesarean delivery, composite maternal and neonatal morbidity, and patient satisfaction (assessed by Birth Satisfaction Scale-Revised). Sub-group analyses for those with BMI ≥ 30 kg/m2 and cervical dilation ≥1 cm were performed. We required 148 subjects to have 80% power to detect a 2-hour difference in time to delivery. The study was stopped early by the data safety monitoring board due to feasibility concerns in recruiting desired sample size. RESULTS: A total of 108 subjects were randomized: 56 oxytocin; 52 oral miso. The median gestational age at induction was 39.5 weeks; the mean starting cervical dilation was 1.1 cm. There was no statistical difference in time to delivery between groups overall: 14.9 hours oxytocin vs 18.1 hours oral misoprostol (P=.06). In sub-group analyses, there was a 5 hours shorter time to delivery with oxytocin for those with a BMI ≥ 30 kg/m2 (16.6 hours oxytocin vs 21.8 hours oral misoprostol, P .04) and 4.5 hours shorter time to delivery with oxytocin for those with cervix ≥1 cm (12.9 hours oxytocin vs 17.3 hours oral misoprostol, P .04). There were no differences in intraamniotic infection, cesarean delivery, maternal or neonatal morbidity between the groups. Patient satisfaction was higher for those receiving oxytocin compared to misoprostol (29.0 vs 26.3, P=.03). CONCLUSION: Among nulliparas with PROM and an unfavorable cervix, there was no difference in overall time to delivery between oxytocin and oral misoprostol. This result should be interpreted with caution given early study discontinuation and inadequate power. However, a shorter time to delivery with oxytocin was noted in obese patients and those with cervical dilation of at least 1 cm. Furthermore, patient satisfaction was higher in the oxytocin group, and there was no increased risk of neonatal or maternal morbidity with oxytocin.

来源:Am J Obstet Gynecol MFM,查看原文。版权归原作者所有。

引用

  1. Bender WR, Mccoy JA, Levine LD, et al. Oxytocin vs oral misoprostol for PROM induction in nulliparas with unfavorable cervix: a randomized trial. Am J Obstet Gynecol MFM. 2024. PMID: 38936618. doi:10.1016/j.ajogmf.2024.101414

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。